7 minute read
Apr. 27, 2023

Revumenib: a Novel Menin-MLL1 Inhibitor in Ph. II for AML

revumenib

oral menin-KMT2A inhibitor Ph. I/II for r/r leukemia, CRC & solid tumors discovery not disclosed Nature, March 15, 2023 Vitae, Madison, NJ / Syndax, Waltham, MA

twitterlinkedinprintemail

MOTY Nominees

Molecule of the Year